Cargando…
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV−2) causes coronavirus disease 2019 (COVID−19). Antibodies induced by SARS-CoV−2 infection or vaccination play pivotal roles in the body’s defense against the virus; many monoclonal antibodies (mAbs) against SARS-CoV−2 have been cloned, and so...
Autores principales: | Tada, Minoru, Aoyama, Michihiko, Ishii-Watabe, Akiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266124/ https://www.ncbi.nlm.nih.gov/pubmed/37309192 http://dx.doi.org/10.1080/19420862.2023.2222874 |
Ejemplares similares
-
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
por: Aoyama, Michihiko, et al.
Publicado: (2021) -
Development of a Cell-Based Assay Measuring the Activation of FcγRIIa for the Characterization of Therapeutic Monoclonal Antibodies
por: Tada, Minoru, et al.
Publicado: (2014) -
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021) -
Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies
por: Aoyama, Michihiko, et al.
Publicado: (2019) -
Development and characterization of an anti-rituximab monoclonal antibody panel
por: Tada, Minoru, et al.
Publicado: (2018)